Bjorner, J. B.
Kennedy, N.
Lindgren, S.
Pollock, R. F.
Funding for this research was provided by:
Pharmacosmos A/S
Article History
Accepted: 27 February 2024
First Online: 14 June 2024
Declarations
:
: RFP is a shareholder, director and full-time employee of Covalence Research Ltd, which received consultancy fees from Pharmacosmos A/S to prepare the data for analysis and prepared the draft manuscript. JBB is Chief Science Officer for QualityMetric, which received consultancy fees from Pharmacosmos A/S to perform the data analyses. NK has received speaker honoraria, support for meetings and/or travel, and participation in an advisory board from Pharmacosmos A/S. SL has no conflicts of interest to declare.
: The present study was based on patient-level data from the PHOSPHARE-IBD trial, which involved human participants and was conducted in line with the Declaration of Helsinki. All patients gave informed consent to participate in the study, and the study was approved by Institutional Review Boards at all participating centers as detailed by Zoller et al. (2022) [].